A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors And Lymphomas
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients with treated brain metastases are eligible if the brain metastases are stable and the patient does not require radiation therapy or steroids. Active screening for brain metastases is not required 2) Patients with NSCLC: o Must have received prior treatment with platinum-based therapy (unless intolerant or not suitable) and a PD-1 PD-L1 inhibitor. A checkpoint inhibitor should have been administered if approved for the patient's indication in their locality, alone or in combination with other therapy. o Patients with advanced or metastatic stage IV NSCLC with epidermal growth factor receptor (EGFR) or anaplastic l mphomakinase (ALK) genomic alterations are eligible if they have progressed on treatment or did not tolerate appropriate targeted therapy. This would include osimertinib for T790M mutation-positive NSCL o Patients with NSCLC with known ROS1 rearrangement must have received prior treatment with crizotinib o Patients with B-raf mutations must have received prior treatment with a B-raf inhibitor

You may not be eligible for this study if the following are true:

  • 1) Serious concurrent illness, including, but not limited to, the following: o Clinically relevant infection, including known active hepatitis B or C, human immunodeficiency virus, or non-viral infection requiring antibiotics. o Significant cardiac disease, such as recent myocardial infarction (=6 months prior to Cycle 1 Day 1), unstable angina pectoris, uncontrolled congestive heart failure (New York Heart Association >Class II), uncontrolled diabetes (hemoglobin A1c [HbA1c] >7%) uncontrolled hypertension (NCI CTCAE Version 5.0 Grade 3 or higher), uncontrolled cardiac arrhythmias, severe aortic stenosis, or =Grade 3 cardiac toxicity following prior chemotherapy. o History of hemorrhagic or ischemic stroke within the last 6 months, or clinically significant alcoholic liver disease 2) Use of iron chelators 3) Major surgery within 3 months prior to study enrollment 4) Live vaccine within 28 days prior to planned dose

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.